Vir Biotechnology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vir Biotechnology sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Vir Biotechnology: 13 sponsored US clinical trials, 3 recruiting.
Vir Biotechnology sponsors 13 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV I Infection, with 1 trials.
Top-decile sponsor footprint
Vir Biotechnology ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
13 total, page 1 of 1
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06960395
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
NCT05997615
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
NCT05484206
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
NCT04856085
A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
NCT05844228
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
NCT05567783
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
NCT05280717
A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants
NCT04988152
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
NCT04913675
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
NCT04779879
VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
NCT04725877
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
NCT04545060
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Vir Biotechnology pipeline
3 recruiting of 13 indexed (23% open); 5 completed (38%).
Phase mix: 2 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: HIV I Infection (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vir Biotechnology: open-pipeline peers nationwide
Peers matched on 13 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Vir Biotechnology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 23% open enrollment (± trial volume)
- Clemson University · 23% recruiting · 13 trials
- Liberating Technologies · 23% recruiting · 13 trials
- Rahul Aggarwal · 23% recruiting · 13 trials
- Sequenom · 23% recruiting · 26 trials
Related
What to do with this Vir Biotechnology page
13 registered trials is a research-attention snapshot, not an endorsement of Vir Biotechnology or any single study.
- 3 of Vir Biotechnology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV I Infection is the condition Vir Biotechnology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV I Infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vir Biotechnology pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.